Asymptomatic Bacteriuria (ASB) in diabetic patients: Treat or not to treat: A prospective, observational study conducted at a tertiary care hospital

Abubakar Tauseef¹, Maryam Zafar², Erum Syyed³, Joseph Thirumalareddy⁴, Akshat Sood⁴, Mohsin Mirza⁵

¹Resident Physician, ⁴Hospitalist, ³Associate Program Director, Department of Internal Medicine, Creighton University Hospital Program, Omaha, NE, USA, ²Resident Physician in Department of Internal Medicine, Dow University of Health Sciences, ³Medical Student at Dow University of Health Sciences, Karachi, Pakistan

ABSTRACT

Background: The term asymptomatic bacteriuria (ASB) refers to the isolation of bacteria in a urine specimen of individuals who denied symptoms of urinary tract infection. Diabetes mellitus (DM) is a disease involving multiple organ systems, hallmarked for its chronicity and thus-forth endless complications including asymptomatic bacteriuria. Objectives: This study aimed to determine the characteristics of asymptomatic bacteriuria and antibiotic susceptibility pattern amongst patients with diabetes. Settings and Design: A prospective observational study was conducted at a tertiary care hospital in Karachi, Pakistan. Methods and Material: The study included all those patients with a diagnosis of diabetes with no signs and symptoms of urinary tract infection but showing the growth of an organism in urine culture. Pregnant females and subjects who used antibiotics in last two weeks were excluded. A total of 222 urine cultures were observed prospectively who met the inclusion criteria through non-probability consecutive sampling. Results: Out of 222 urine cultures observed, mean age of subjects were 62.89 ± 13.77 out of which 76% were females, and 61% had a family history of diabetes. The most frequent organisms isolated were Escherichia Coli (E. Coli), Enterococcus, Klebsiella, Pseudomonas, and Enterobacter species. A total of 20 subjects got dual bacterial growth in their cultures among which 17 subjects had a growth of Enterococcus with any other pathogen causing UTI. Gender, family history of diabetes, levels of HBA1c, and older age groups all were found significantly associated with ASB. Conclusions: Our study is the first to analyze and study the associated risk factors amongst ASB in DM patients, and to identify the pathogens involved along with assessing their antibiotic resistance profiles. Also, due to the increase resistance to antibiotics we would recommend to use antibiotics in ASB patients only if they have any two or more comorbidities.

Keywords: Asymptomatic, bacteria, culture, diabetes, urine

Introduction

Diabetes mellitus, hallmarked for its chronicity and endless complications, occurs due to a defect in the production or utilization of insulin.⁶ According to the International Diabetes Federation, approximately 425 million adults worldwide had diabetes out of which, 79% belonged to countries with low socioeconomic status.⁶ According to the survey conducted in 2017, the prevalence of type 2 diabetes is reported to be 16.98%.⁶ With this disease on the rise, diabetes mellitus has become a hot topic of discussion ultimately leading to further elaboration of disease processes that can ensue due to the initial ailment of it. Diabetes mellitus is notorious for causing cardiovascular, neurological, and renal insult.⁶,⁷ Diabetes has
a negative impact on humoral immunity and neutrophilic function, it also damages the antioxidant system, evidently making patients prone to infections of any organ system of the body including infection of the urinary tract. Even after treatment, re-infection is common amongst diabetics. Considering this information, asymptomatic bacteriuria amongst diabetics poses an imminent threat of progressing from urethritis to life-threatening pyelonephritis in a matter of no time.

Asymptomatic bacteriuria (ASB) is the existence of bacteria in the urine with no clinical signs and symptoms of a UTI. It is detected via urine culture of a properly collected urine specimen as per certified medical guidelines. ASB is diagnosed either upon the presence of 100,000 colony forming units per ml in a midstream clean catch urine sample or upon the presence of 100 CFU per ml in the urine sample obtained from a catheterized patient. While E. Coli is the most common organism, atypical pathogens with increased antimicrobial resistance are found more in the urine cultures of the former. With an increased risk of upper urinary tract involvement and the likelihood of ASB progressing to a symptomatic UTI in this patient population, having urine samples cultured both pre and post-treatment are suggested.

Diabetic patients with ASB often tend to experience pyelonephritis and albuminuria. Past studies have shown that women with diabetes are three times more likely to have ASB. Diabetics mostly get admitted for a complication of ASB including acute pyelonephritis, which affects 3.4-17% of diabetic males and 6-24 times of women. Diabetic patients are prone to get ASB complications. The most serious of which, being renal abscess, emphysematous pyelonephritis, renal papillary necrosis and urosepsis. Furthermore, it has been proposed in previous studies that diabetic patients with ASB may recede with greater frequency toward renal failure several years forth. Patients with urinary tract infection in diabetic patients are usually sensitive to ciprofloxacin or gentamicin.

Materials and Methodology

A prospective observational study conducted in the internal medicine department of tertiary care hospital for the duration of 6 months. A sample size of 220 was calculated by using a Rao-sof soft sample size calculator (http://www.raosoft.com/samplesize.html). Permission was taken from the Institution of Review Board (approval no. IRB/DUHS/2019/108/085) and informed consent were taken from all the participants of the study. Consent was taken from all patients and ethical committee approval was taken back in 03/15/2020.

Clean voided, mid-stream urine samples were collected from all the subjects and processed following standard guidelines. Urine gram stain examination was done to look for the pus cells and bacteria. In patients with significant bacteriuria, antibiotic susceptibility was done according to clinical laboratory standards institute (CLSI) guidelines. For diagnosing ASB in females, two consecutive specimens with isolation of the same species in quantitative counts of at least 100,000 colony forming units (CFUs)/mL of urine were considered, whereas in males, a single specimen with one bacterial species isolated in a quantitative count of at least 100,000 CFUs/mL was considered. Patient with urine analysis confirming bacterial infection but without any signs and symptoms of UTI were included in our study.

After the data collected through the non-probability consecutive sampling method, it was analyzed on IBM-SPSS version 25.0 and results were obtained. The statistical difference was calculated via independent sample t-test, Chi-square, and fisher's exact test, and considered significant if <0.05.

Results

Out of the 222 subjects, three times more women with a younger mean age of 61.54 ± 13.86 as compared to men were recruited. Around 58% of males had a family history of Diabetes Mellitus (DM), in contrast to 62% of females. 28.37% of females had a known history of Chronic Kidney Disease (CKD) in contrast to 9% among males. 36% of females had hypertension while this number was 14.28% among males. Ischemic heart disease was found to be in 4.95% of females and 4.50% of males respectively. Almost 40% of the subjects had there HBA1c in the range of 6.5-9.0%, 22% in the range of 5.7-6.5%, remaining were equally distributed in the range of <5.7%, 9-11.5%, 11.6-14.0% and greater than 14.0% respectively.

Enterococcus species and Klebsiella pneumonia were the most prevailing organisms being isolated from the urine samples of all the subjects, with the frequency of 54%, 13%, 11% among females and 49%, 11% and 9% among males. Male growth was observed in 20 of the total subjects, out of which 16 were females. 43.75% of the dual growth among females isolated E. Coli and Enterococcus species while 18.75% isolated Enterococcus with Klebsiella species. In contrary 75% of the dual growth among males showed the growth of Enterococcus and E. Coli while 25% showed Enterococcus and Proteus Mirabilis.

Escherichia Coli, Enterococcus species, and Klebsiella pneumonia were the most prevailing organisms being isolated from the urine samples of all the subjects, with the frequency of 54%, 13%, 11% among females and 49%, 11% and 9% among males. Male growth was observed in 20 of the total subjects, out of which 16 were females. 43.75% of the dual growth among females isolated E. Coli and Enterococcus species while 18.75% isolated Enterococcus with Klebsiella species. In contrary 75% of the dual growth among males showed the growth of Enterococcus and E. Coli while 25% showed Enterococcus and Proteus Mirabilis.

Once diagnosed with diabetes mellitus, patients require lifelong insulin therapy or adjunctive therapy with this hormone to control glycemic levels. Adequate metabolic control not only limits complications of the disease but also lowers the risk of acquiring infection in an already susceptible diabetic patient. In addition to adequate management, WHO recommends monitoring for adverse effects that can come about due to this disease. Among the interventions suggested is screening for pathologies that can later proceed to manifest as kidney disease. In view of this guideline and the projected estimate of diabetes mellitus on the rise especially in countries with low socioeconomic status, considering the paucity of data regarding findings of asymptomatic bacteriuria amongst the diabetic population in Pakistan, urged to conduct this study. The primary objective of this study is to determine the characteristics of asymptomatic bacteriuria in diabetes mellitus patients.
Out of the 20 subjects who got a dual growth in their cultures, 13 had a positive family history for DM.

Amongst the cultures that came positive, E. coli (n = 129) was found most sensitive to Amikacin (84.49%) followed by Fosfomycin (80.62%) and Gentamicin (66.67%). The resistance was mostly documented to Ampicillin (86.04%) followed by cefixime (82.94%) and cefuroxime (82.17%). Amongst the 27 positive cultures of Klebsiella pneumonia, the most sensitive antibiotic was Fosfomycin (70.37%) followed by:

Amikacin (55.56%) and Piperacillin/Tazobactam (44.44%), while the most resistances were Ceftriaxone (77.78%), Cefixime (77.78%), and Cefuroxime (74.07%) respectively. Pseudomonas was positive in 10 cultures, being most sensitive to Ciprofloxacin (70%) followed by Ceftazidime (60%) and Amikacin (60%) and being also most resistant to Ceftazidime (40%), [Table 1].

Amongst the patients with chronic kidney disease (n = 83), Enterococcus was the most likely organism to be positive in urine culture with 57.8% infecting (n = 26), while rest 42.2% (n = 19) infecting non-CKD patients (p = 0.002). While E. coli was positive in only 35 CKD patients (27.1%), the rest 94 cultures (62.9%) were infected in non-CKD patients (p = 0.0002). Enterobacter was exclusively present in the cultures of patients with CKD, with all the 9 growths (100%) opposed to no growths in non-CKD patients (p = 0.0001), which showed that patient with underlying CKD are at very high risk of ASB and its complications including pyelonephritis or perinephric abscess.

With respect to patients presenting with no other co-morbidities except for diabetes (n = 70), E. coli was mostly likely associated organism (n = 52) with a P value of 0.001. Enterococcus was opposed to more likely occurring in patients with multiple co-morbidities (p = 0.010). With respect to patients with Benign prostatic hyperplasia (n = 22), E. coli was infecting 50% of their cultures (n = 11), among others (p = 0.561). Considering BPH as a prevalent co-morbid in the old age males, yet the frequency of asymptomatic bacteriuria in BPH is quite low as compared to other co-morbidities in our study population (9.90%). It can be postulated that even though BPH is considered as a significant risk factor of asymptomatic bacteriuria, it is more likely to cause symptomatic urinary infections rather than asymptomatic ones. Urinary tract infection prevalence is increasing as the time passes. Factors like diabetes, hypertension and female gender put you at high risk to get a urinary tract infection, so in such scenario the prevalence of urinary tract infection without any symptoms is also very high. This study is of great benefit for the primary care physicians as after analysis of the results, we recommend the initiation of antibiotics in patient having asymptomatic bacteriuria but with two or more risk factors, as by doing this we can prevent the symptoms to develop and to prevent the complications which can be caused if bacteriuria stayed untreated.

Discussion

Many studies investigated the risk factors associated with ASB in DM patients. This study aimed to outline the associated risk factors of ASB in DM, the pathogens involved, and their antibiotic sensitivity profiles.

Various studies conducted have shown demographic factors (particularly age and female gender) to be associated with ASB in DM patients. Such is the case in our study with results showed that the mean age of our patients was (62.89 ± 13.77), similar to Geerlings et al., (63.0 ± 10) Turan et al., (60.8 ± 9.5) and Odetoyin et al., (65.52 ± 9.4),[27,28,29] The mean age in our study however differed from the findings of Hamdan et al., Boroumand et al., and Zhanel et al., which reported lower mean ages.[30,31,32] The greatest percentage of patients with ASB in our study were found in the 50-75 years age range, with 66.7% of the total study population falling in this group. This age range was comparable to Melland et al., where 61.8% of the diabetic patients positive for ASB were in the 56-75 years age range.[34]

Various studies have confirmed the role of the female sex as a risk factor for ASB in diabetics, like study by Turan et al., where 77.2% of females were positive for ASB.[28] Results from the studies by Jha et al., (70%) and Alebiosu et al., (72.7) reported similar results as well, while Banerjee et al., reported a lower frequency (59%).[33,34,35] Bissong et al., and Matteucci et al., however recorded higher percentages of women in their studies at 86.4% and 86% respectively, and thus concluding that the female gender was a positive risk factor for ASB.[10,37] The high prevalence of women in our study population can be since most of the women have undergone postmenopausal changes (the mean age of women in this study was 61.54 ± 13.86).[38]

The role of glycemic control (HbA1c) as a risk factor for diabetic patients to develop ASB has been controversial. Studies in the literature are both for and against its role as a risk factor. Turan et al., confirmed in their study as poor glycemic control to be a risk factor for ASB.[28] The mean HbA1c reported was (8.7 ± 2.0), which is like our study.[29] A study in India on diabetic patients showed 71.43% of their patients had poorly controlled DM.[39] Matteucci et al. reported mean HbA1c of 7.9 ± 1.1, slightly lower compared to our results.[37] Bonadio et al., reported mean HbA1c of 9.6 ± 2.0, higher than our findings.[34] The mean HbA1c reported by Zhanel et al., was higher than our results at 13.3 ± 4.1, but they too concluded that HbA1c and ASB are not related.[33] Similar conclusions have been reached by Nicolle et al., and He et al.[20,40] The inconsistent variability among the relation between glycemic control and ASB reflects the variety of study populations and the selection criteria used in these studies.

Zhanel et al., reported that 5.9% of their patients had kidney disease, much lower than our study.[19] The high prevalence of CKD in our study could be due to diabetic nephropathy, or the effect of ASB and DM collectively on the kidneys. An interesting result in our study was related to the pathogens cultured in
Table 1: Frequency of susceptibility to antibiotics of microorganisms isolated in the cultures

| Antibiotics | 1. Staph Aureus | 2. MRSA | 3. Enterococcus | 4. Streptococcus | 5. P. Aeruginosa | 6. E. Coli | 7. K. Pneumonia | 8. Proteus Mirabilis | 9. Acinetobacter | 10. K. Oxytoca | 11. Burkholderia Cepacia | 12. Enterobacter | 13. Citrobacter |
|-------------|----------------|--------|----------------|-----------------|-----------------|--------|----------------|-----------------|----------------|-------------|-------------------|----------------|----------------|
| Aztreonam   | Sensitive      | 0      | 0              | 0               | 0               | 0      | 0              | 0               | 0              | 0           | 0                  | 0              | 0              |
|             | Resistant      | 0      | 0              | 0               | 1               | 1      | 2              | 0               | 0              | 0           | 0                  | 0              | 0              |
| Amikacin    | Sensitive      | 4*     | 2*             | 2               | 6*              | 109*   | 15*            | 1^              | 0              | 2*          | 0                  | 3*             | 1*             |
|             | Resistant      | 0      | 1^             | 1               | 0               | 3^     | 8               | 10              | 0              | 1*          | 2^                  | 0              | 5^             |
| Amoxicillin/ | Sensitive      | 1      | 0              | 21^             | 5^              | 0      | 57              | 8               | 2*             | 0           | 2*                  | 0              | 0              |
| Clavulanic acid | Resistant  | 0      | 3*             | 1               | 0               | 58     | 16              | 0               | 2^             | 0           | 0                  | 0              | 0              |
| Ampicillin  | Sensitive      | 0      | 20             | 5*              | 0               | 4      | 1               | 2*              | 0              | 0           | 0                  | 0              | 0              |
|             | Resistant      | 0      | 0              | 20*             | 0               | 0      | 111*            | 2               | 0              | 1          | 0                  | 1              | 0              |
| Ciprofloxacin | Sensitive     | 3^     | 0              | 1               | 0               | 7*     | 33              | 4               | 1^             | 0           | 1                  | 0              | 2              |
|             | Resistant      | 1*     | 1^             | 5               | 0               | 3^     | 87              | 19              | 0              | 2*          | 3*                  | 0              | 7*             |
| Ceftriaxone | Sensitive      | 0      | 0              | 1               | 3               | 0      | 20              | 5               | 1^             | 1^          | 1^                  | 0              | 2              |
|             | Resistant      | 0      | 0              | 3               | 0               | 0      | 99              | 21*             | 0              | 1^          | 2^                  | 0              | 7*             |
| Cefixime    | Sensitive      | 0      | 0              | 2               | 0               | 0      | 22              | 5               | 1^             | 0           | 1                  | 0              | 2              |
|             | Resistant      | 0      | 0              | 1               | 0               | 0      | 107             | 21*             | 0              | 3*          | 0                  | 7*             | 1*             |
| Cefuroxime  | Sensitive      | 0      | 0              | 1               | 0               | 0      | 22              | 6               | 1^             | 0           | 1                  | 0              | 2              |
|             | Resistant      | 0      | 0              | 2               | 0               | 0      | 106             | 20*             | 0              | 0           | 3*                  | 0              | 7*             |
| Co-trimoxazole | Sensitive   | 0      | 0              | 2               | 0               | 0      | 36              | 3               | 1^             | 0           | 1^                  | 1*             | 2              |
|             | Resistant      | 0      | 1               | 0               | 0               | 57     | 14              | 0               | 2*             | 0           | 2*                  | 1              | 1*             |
| Gentamicin  | Sensitive      | 4*     | 1              | 3               | 0               | 4      | 86              | 11              | 0              | 1^          | 0                  | 4^             | 0              |
|             | Resistant      | 0      | 1^             | 1               | 0               | 3^     | 33              | 14              | 0              | 1^          | 3*                  | 0              | 5^             |
| Meropenem   | Sensitive      | 0      | 0              | 1               | 0               | 0      | 4               | 85              | 11             | 0           | 2*                  | 0              | 1*             |
|             | Resistant      | 0      | 0              | 0               | 0               | 0      | 2               | 7               | 7              | 0           | 2^                  | 0              | 4              |
| Piperacillin/ | Sensitive     | 0      | 0              | 3               | 0               | 7*     | 81              | 12              | 1^             | 2*          | 1                  | 0              | 2*             |
| Tazobactam  | Sensitive      | 0      | 0              | 0               | 0               | 3^     | 34              | 13              | 0              | 2^          | 0                  | 5^             | 0              |
| Vancomycin  | Sensitive      | 3^     | 3*             | 18              | 1               | 0      | 0               | 0               | 0              | 0           | 0                  | 0              | 0              |
|             | Resistant      | 0      | 0              | 12              | 0               | 0      | 0               | 0               | 1              | 0           | 0                  | 0              | 0              |
| Fosfomycin  | Sensitive      | 0      | 0              | 32*             | 4*              | 1      | 104*            | 19*             | 2*             | 1^          | 1^                  | 0              | 4^             |
|             | Resistant      | 0      | 0              | 7               | 1               | 0      | 16              | 5               | 0              | 1           | 0                  | 1              | 4              |
| Nitrofurantoin | Sensitive    | 3^     | 1              | 13              | 1               | 0      | 51              | 8               | 0              | 0           | 1^                  | 0              | 1              |
|             | Resistant      | 0      | 5               | 0               | 0               | 2      | 1               | 1               | 0              | 1           | 0                  | 1              | 0              |
| Levofloxacin | Sensitive     | 0      | 0              | 7               | 3               | 0      | 4               | 1               | 1^             | 0           | 0                  | 0              | 1^             |
|             | Resistant      | 0      | 0              | 26*             | 2*              | 1      | 8               | 5               | 0              | 1           | 1^                  | 0              | 3              |
| Colomycin/  | Sensitive      | 0      | 0              | 0               | 0               | 0      | 2               | 6               | 8              | 0           | 0                  | 2*             | 0              |
| Polymyxin B | Resistant      | 0      | 0              | 0               | 0               | 0      | 0               | 0               | 0              | 0           | 0                  | 0              | 0              |
| Tobramycin  | Sensitive      | 0      | 0              | 0               | 0               | 0      | 0               | 0               | 0              | 0           | 0                  | 0              | 0              |
|             | Resistant      | 0      | 0              | 0               | 0               | 0      | 1               | 6               | 7              | 0           | 2^                  | 0              | 4              |
| Sulbactam/  | Sensitive      | 0      | 0              | 0               | 0               | 0      | 0               | 0               | 0              | 0           | 0                  | 0              | 0              |
| Cefoperazone | Resistant      | 0      | 0              | 0               | 0               | 0      | 1               | 6               | 8              | 0           | 0                  | 2^             | 0              |
| Ceftazidime | Resistant      | 0      | 0              | 0               | 0               | 0      | 0               | 0               | 0              | 0           | 0                  | 0              | 1*             |
| Linezolid   | Sensitive      | 0      | 0              | 0               | 0               | 0      | 0               | 0               | 0              | 0           | 0                  | 0              | 0              |
| Cloxacillin | Sensitive      | 4*     | 0              | 0               | 0               | 0      | 0               | 0               | 0              | 0           | 0                  | 0              | 0              |
|             | Resistant      | 0      | 3^             | 0               | 0               | 0      | 0               | 0               | 0              | 0           | 0                  | 0              | 0              |

*Most Sensitive/Resistance antibiotic amongst the particular Organism. 2nd most Sensitive/Resistance antibiotic amongst the particular Organism.
patients with CKD as comorbidity. Our results showed that Enterococcus was present in 57.8% of these patients. A study on renal transplant patients found Enterococcus to be present in 35% of the cultures. Hypertension was reported to be 12% as reported by Meiland et al.\footnote{34} Tencer et al., reported 37.5% of their patients to be hypertensive, while even greater frequencies were found by Papazafiropoulou et al., (79.5%) and Kasyan et al., 87.3\%\footnote{30,38,41}.

A study conducted in Sudan showed the growth of E. coli (56.4\%), K. Pneumoniae (23.0\%), and E. faecalis (12.8\%) in the urine culture.\footnote{31} Klebsiella pneumonia (42.4\%), E. coli (21.2\%), and E. faecalis (12.1\%) were isolated from the study in Nigeria,\footnote{19} while E. coli (67\%), Enterococcus (9\%), Klebsiella (14\%) were found in the study conducted in Southern India.\footnote{42} Odeto\-\text{yin et al.}, performed a study where the isolated organisms were Staphylocoecal aureus (80.9\%), Klebsiella (9.5\%), Enterococcus faecalis (4.8\%), and E. coli (4.8\%).\footnote{40}

One of the aims of our study was to assess the antibiotic sensitivity and resistance present in each organism cultured. We found that E. coli was mainly susceptible to aminoglycosides and Fosfomycin, with resistance mainly to Ampicillin and 3rd generation cephalosporins. Nigussie et al., found that E. coli was sensitive to nitrofurantoin (100\%), norfloxacin (90.9\%), ciprofloxacin (81.8\%), but resistant to Ampicillin (100\%), trimethoprim-sulfamethoxazole (81.8\%), gentamicin (72.7\%).\footnote{43} This study also showed that E. coli was resistant to Gentamicin (72.7\%),\footnote{43} but our study showed it was susceptible to Gentamicin (66.7\%). The resistance of E. coli in this study to Ampicillin was 100\%,\footnote{43} compared to our results which shows a resistance of 86.04\%. Our study showed a 67.4\%
resistance to Ciprofloxacin as compared to the 81.8% sensitivity in the study by Nigussie et al., Bissong et al., in their analysis found E. coli was resistant to Nalidixic acid 33.3%, Gentamicin 26.7%, and Cefuroxime 13.3%. These results differed from ours as Gentamicin was sensitive in 66.7% of the organisms, and the resistance of Cefuroxime was much higher in our study (82.17% v 13.3%). A study conducted in India found E. Coli to be 100% sensitive to Imipenem, but 90% resistant to 3rd generation cephalosporins, thus resembling the resistance pattern of E. Coli seen in our study.

K. pneumonia was susceptible to Fosfomycin (70.37%) followed by Amikacin (55.56%) and Piperacillin/Tazobactam (44.44%) while showing resistance mostly to the cephalosporins. A study in China showed that K. pneumonia was resistant to Amoxicillin (100%), Cephalothin (50%), Cefuroxime (41.7%). These results are in agreement with our findings that show high resistance to cephalosporins. Our study showed a lower resistance of K. pneumonia to Amoxicillin as compared to the results shown in this study (59.2% v 100%). Alebiosu et al., found that K. pneumonia was susceptible to gentamicin and ciprofloxacin in 85.7% of the organisms, nitrofurantoin in 78.5%, and 71.4% in ofloxacin. Our antibiotic profile for K. pneumonia shows its susceptibility to Gentamicin in 40.7% cases, 14.8% to ciprofloxacin, and 29.6% to nitrofurantoin, while showing the susceptibility of the organism to all antibiotics were much lower.

The most sensitive antibiotics for enterococcus were fosfomycin (71.1%), amoxicillin (46.67%), and vancomycin (40%). Enterococcus showed resistance mainly to levofloxacin (57.78%) and ampicillin (44.44%). He et al., showed that enterococcus in their studies was resistant to levofloxacin as well (33.3%), but the resistance to the antibiotic seen in our study was greater. Hamdan et al., documented ampicillin to be sensitive to 80% of the organism, while we found the sensitivity to ampicillin in our study was much lower. A study in Southern India placed the sensitivity of the pathogen to vancomycin at 89%, which was much greater as to sensitivity seen to the same antibiotic in our study.

We also found that Candida was present in 12.16% of the organisms cultured. These results closely mimic the findings of Jha et al., who found a prevalence of 16.67% of the organism. A much higher percentage was however seen in diabetic patients with ASB in India, where 7 cases of candida were isolated from a total of 21 species (33.33%).

A few limitations can be noted in this study. The study took place at a single tertiary care hospital in an urban city. The sexual hygiene, socioeconomic status, urinary catheterization, and the duration of diabetes was not taken into account for our subjects.

Conclusions

Despite many studies present in the literature (about ASB in DM patients) with their diverse protocols and study populations, data regarding the risk factors of ASB in DM patients in Pakistan was scarce. In this regard, our study is the first to analyze and study the associated risk factors amongst ASB in DM patients, and to identify the pathogens involved along with assessing their antibiotic resistance profiles. Based on our results we recommend similar studies should be conducted in the region, to improve and develop the guidelines and protocols on managing patients with ASB and DM. But from the limited data which we got from our study. We would recommend that doctors or nephrologist should plan to start antibiotics prophylactically with a caution because of high prevalence of resistance to antibiotics, so our recommendation would be to use antibiotics prophylactically only if patient had two or more comorbidities in order to prevent the complications that can be caused by ASB like pyelonephritis, perinephric abscess etc.

Key points

- This study showed the statistical data of bacterial culture growth in diabetic patient and antibiotic sensitivity against those specific micro-organisms
- Study proved that in diabetic patients if patient had two or more co-morbidities, he or she should be treated prophylactically which is a take home message to our study.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

This work is not supported by any sponsors. No funding required in this study.

Conflicts of interest

There are no conflicts of interest.

References

1. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 2012;16(Suppl 1):S27-36.
2. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet JT, Schneeberger PM, et al. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med 2001;161:1421-7.
3. Lienhard GE, Slot JW, James DE, Mueckler MM. How cells absorb glucose. Sci Am 1992;266:86-91.
4. International diabetes federation-facts & figures. Available from: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html. [Last accessed on 2019 Sep 30].
5. Aamir AH, U-Haq Z, Mahar SA, Qureshi FM, Ahmad I, Jawa A, et al. Diabetes Prevalence Survey of Pakistan (Dps-pak): Prevalence of type 2 diabetes mellitus and prediabetes using
Tauseef, et al.: Asymptomatic bacteriuria

HbA1c: A population-based survey from Pakistan. BMJ Open 2019;9:e025300. doi: 10.1136/bmjopen-2018-025300.

6. International diabetes federation-home. Available from: https://idf.org/52-about-diabetes.html. [Last accessed on 2019 Sep 30].

6. Diabetes. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes. [Last accessed on 2019 Sep 30].

6. Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J. The role of oxidative stress and antioxidants in diabetic complications. Sultan Qaboos Univ Med J 2012;12:5-18.

6. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Influence of diabetes mellitus on the spectrum of uropathogens and antimicrobial sensitivity among diabetic patients. J Urol 1999;341:1906-12. doi: 10.1016/NEJM199912163412507.

6. Perschel WT, Langefeld TW, Federlin K. [Susceptibility to infections in diabetes—effects on metabolism]. Immun Infect 1995;23:196-200.

6. Colgan R, Nicolle LE, McGlone A, Hooton TM. Asymptomatic bacteriuria in adults. Am Fam Physician 2006;74:985-90.

6. Givler DN, Givler A. Asymptomatic bacteriuria. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2019. Available from: http://www.ncbi.nlm.nih.gov/books/NBK441848/. [Last accessed on 2019 Oct 04].

6. Papazafiropoulou A, Daniil I, Sotiropoulos A, Balampani E, Kokolaki A, Bousbouslas S, et al. Prevalence of asymptomatic bacteriuria in type 2 diabetic subjects with and without microalbuminuria. BMC Res Notes 2010;3:169.

6. Kayima JK, Ottieno LS, Twahir A, Njenga E. Asymptomatic bacteriuria among diabetics attending Kenyatta National Hospital. East Afr Med J 1996;73:524-6.

6. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med 2002;113(Suppl 1A):80S-4S.

6. Bonadio M, Costarelli S, Morelli G, Tartaglia T. The influence of metabolic control. Clin Infect Dis 2004;38:e41-5.

6. Forghani S. Asymptomatic bacteriuria in type 2 Iranian diabetic women: A cross sectional study. BMC Womens Health 2006;6.

6. Zhanel GG, Nicolle LE, Harding GK. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. The Manitoba Diabetic Urinary Infection Study Group. Clin Infect Dis 1995;21:316–22.

6. Meiland R, Geerlings SE, Stolk RP, Netten PM, Schneeberger PM, Hoepelman AI. Asymptomatic bacteriuria in women with diabetes mellitus: Effect on renal function after 6 years of follow-up. Arch Intern Med 2006;166:2222-7.

6. Jha BK, Singh YI, Khanal LK, Yadab VC, Sanjanka RK. Prevalence of asymptomatic bacteriuria among elderly diabetic patients residing in Chitwan. Kathmandu Univ Med J (KUMJ) 2009;7:157-61.

6. Banerjee M, Majumdar M, Kundu PK, Maisnam I, Mukherjee AK. Clinical profile of asymptomatic bacteriuria in type 2 diabetes mellitus: An Eastern India perspective. Indian J Endocr Metab 2019;23:293-7.

6. Matteucci E, Trollo A, Leonetti P, Giampietro O. Significant bacteriuria in outpatient diabetic and non-diabetic persons. Diabet Med 2007;24:1455–9.

6. Kasyan G, Berketova TY, Rogozin AK, Pushkar DY. Asymptomatic bacteriuria in postmenopausal women with diabetes mellitus. Cent Eur J Urol 2013;66:320-6.

6. Bharti A, Chawla SP, Kumar S, Kaur S, Soin D, Jindal N, et al. Asymptomatic bacteriuria among the patients of type 2 diabetes mellitus. J Family Med Prim Care 2019;8:539-43.

6. He K, Hu Y, Shi JC, Zhu YQ, Mao XM. Prevalence, risk factors and microorganisms of urinary tract infections in patients with type 2 diabetes mellitus: A retrospective study in China. Ther Clin Risk Manag 2018;14:403–8.

6. Tencer J. Asymptomatic bacteriuria—A long term study. Scand J Urol Nephrol 1988;22:31-4.

6. Kiranmala K, Johnson R, Savio J, Idiculla J. Microbiologic profile and clinical practices in urinary tract infections in a tertiary care hospital. East Afr Med J 1996;73:524-6.

6. Alebiosu CO, Osinupebi OA, Olajubu FA. Significant asymptomatic bacteriuria among Nigerian type 2 diabetics. J Natl Med Assoc 2003;95:344-9.

6. Bissong MEA, Fon PN, Tabe-Besong FO, Akenji TN. Asymptomatic bacteriuria in diabetes mellitus patients in Southwest Cameroon. Afr Health Sci 2013;13:661-6.

6. Pozzilli P, Leslie RD. Infections and diabetes: Mechanisms and prospects for prevention. Diabet Med 1994;11:935-41.